Decision Resources Research Reports

Title	Published	Price
2005 Chartbook of International Pharmaceutical Prices By: Decision Resources In today’s increasingly price-sensitive environment, pharmaceutical companies must be aware of international price differentials. Many studies have compared retail prices in different countries, but international comparisons of pharmaceutical prices at the ex-manufacturer level are relatively \| more...	12/22/2005	$1,012.50
2005 News in Review: Important Changes for the Pharmaceutical Industry By: Decision Resources This report casts a look back at 2005 and reviews key events and issues in the news that have had a major impact on the pharmaceutical industry or will help shape the industry in the \| more...	12/22/2005	$1,012.50
2006 Chartbook of International Pharmaceutical Prices By: Decision Resources In an ever more globalized pharmaceutical market, drug pricing and reimbursement continue to differ markedly from one country to another. Payers jealously guard their authority to set prices, and they will exert growing pressure on \| more...	6/30/2006	$1,112.50
2006 Financings: IPOs and Pharma’s Acquisitions of Private (IPO-less) Companies By: Decision Resources Private start-up life sciences companies use at least two different financing strategies: sell the whole company to a larger pharmaceutical company or sell shares of the company on a public market. While these young companies \| more...	12/8/2006	$1,112.50
2006 Industry Dynamics: Lessons to Be Learned By: Decision Resources Stunning successes and startling failures highlight 2006’s pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for \| more...	12/21/2006	$1,112.50
2007 Chartbook of International Pharmaceutical Prices By: Decision Resources Introduction: Pharmaceutical companies are increasingly subjected to the dynamics of a globalized pharmaceutical market, and drug pricing and reimbursement continue to vary widely country to country. In a price-sensitive environment such as this, pharmaceutical companies \| more...	6/14/2007	$2,250.00
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry By: Decision Resources The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry are \| more...	9/15/2009	$2,250.00
Acute Ischemic Stroke By: Decision Resources IV reperfusion agent approved for use within six hours of acute ischemic stroke. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market potential \| more...	3/30/2008	$5,625.00
Advances Imminent in Anti-Angiogenesis Therapeutic By: Decision Resources Angiogenesis inhibitors have interested cancer researchers since 1971, when Judah Folkman demonstrated that tumor growth depends on angiogenesis. Despite many efforts to develop angiogenesis inhibitors, however, this drug class has experienced a long and difficult \| more...	4/1/2005	$1,012.50
Advances in the Treatment of Serious Systemic Fungal Infections - An Update By: Decision Resources Opportunistic fungal infections are a major problem in immunocompromised patients. In recent years, the number of patients with severe immunosuppression has risen dramatically as a result of advances in the treatment of HIV/AIDS, cancer, and \| more...	3/18/2005	$1,012.50
Advancing Drug Discovery Through Structure-Guided Drug Design By: Decision Resources Knowledge of protein structure is extremely valuable in drug discovery and development and extremely difficult to obtain. To date, researchers have determined 3D protein structures for only a small percentage of known genomic sequences, largely \| more...	4/19/2005	$1,012.50
Alzheimer's Disease (Moderate to Severe) By: Decision Resources A symptomatic therapy with efficacy greater than that of memantine as measured by the Severe Impairment Battery (SIB) at 28 weeks for the treatment of moderate-to-severe AD. Using Target Product Profiles in Your \| more...	3/30/2008	$5,625.00
An Exploration of Consolidation in the Generics Industry By: Decision Resources The generics industry worldwide is undergoing an unprecedented period of consolidation. This trend began in the United States during the early and mid 1990s, but the focus turned to Europe and India in the late \| more...	12/6/2005	$1,012.50
An Industry in Crisis: Desperately Seeking New Strategies By: Decision Resources The time has come for the pharmaceutical industry to take a hard look at its business strategies and devise new ones more suited to the post-millennium period. The industry has been riding the crest of \| more...	6/30/2006	$1,112.50
An Industry in Crisis: Fixing Pharma's Damaged Reputation By: Decision Resources Reputation is the ultimate business asset. The sustainability and profitability of all businesses depend on their reputation--the trust of all of their stakeholders. Reputation matters; it implies that the company behaves in the best interests \| more...	4/19/2006	$1,112.50
Ankylosing Spondylitis: How Have Biological Therapies Affected the Market? By: Decision Resources Introduction The availability of TNF-á inhibitors fueled a tremendous year-on-year increase in the ankylosing spondylitis (AS) market from 2006 to 2007, and we expect signifi cant growth to continue over the next ten years. Although \| more...	3/23/2009	$2,250.00
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market By: Decision Resources Antibacterial resistance has always been an important driver of innovation for new antibacterial agents. Over the past 10-15 years, resistance to antibacterials in the hospital setting has risen dramatically. Although they are niche segments with \| more...	4/1/2005	$1,012.50
Antitumor Biologics—Strategies for Success in an Expanding Market By: Decision Resources Biological agents are essential tools in cancer treatment, particularly as antitumor drugs. Unsurprisingly, current R&D in this therapeutic area therefore focuses on antitumor agents, predominantly MAbs. While the market is robust-anticancer biologics garnered $9.5 billion \| more...	9/28/2006	$1,112.50
Applications of Stem Cells in Drug Discovery By: Decision Resources Stem cells are unspecialized cells that can differentiate into numerous types of specialized cells with specific functions. Diseases and disorders that might benefit from stem-cell research include Parkinson’s, Alzheimer’s, diabetes, cancer, heart disease, spinal cord \| more...	1/25/2005	$1,012.50
Are Biologics the Wave of the Future? By: Decision Resources Biologics have been good to the pharmaceutical industry—a trend that will continue for the foreseeable future as a raft of new and improved biologics comes to market. Some companies rode the crest of the biologics \| more...	3/30/2007	$1,112.50
Are Genomic and Proteomic Patents Hindering Drug Development? By: Decision Resources Sequencing the human genome resulted in a surge of patents for biomarkers, disease correlations, and their commercial uses. Are these patents now forming a barrier to the development and uptake of diagnostic tests and disease \| more...	11/9/2006	$1,112.50
Are There Changes Ahead for the Generalized Anxiety Disorder Market? By: Decision Resources Introduction Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the major pharmaceutical markets, and drug therapy is considered the most effective treatment. The therapy market for GAD is crowded and includes many generic \| more...	1/26/2009	$2,250.00
Asia: Threat or Opportunity? By: Decision Resources Asian economic might is growing, and the Asian pharmaceutical markets and industry are growing along with it. Western pharmaceutical companies have become very interested in entering Asian markets and taking advantage of the opportunities they \| more...	5/5/2008	$1,669.00
Asthma By: Decision Resources An inhaled drug with a novel mechanism of action for the treatment of persistent asthma. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market \| more...	3/30/2008	$5,625.00
Atopic Dermatitis: Generic Erosion Leads to Stagnant Market By: Decision Resources Atopic dermatitis is one of the largest segments of the dermatology disease market in terms of patient population. However, sales in this market are relative small, primarily because of generics competition. Symptomatic treatment of atopic \| more...	6/23/2006	$1,112.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/21/2009 - 3